Form 4: Cadrenal CFO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Cadrenal Therapeutics' CFO, Matthew K. Szot, sold a total of 1,800 shares of common stock in late September and early October 2025 under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported two sales of the company's common stock.
- On September 29, 2025, Mr. Szot sold 100 shares of common stock at a price of $14.00 per share.
- Following this transaction, Mr. Szot beneficially owned 18,833 shares of common stock.
- On October 1, 2025, Mr. Szot sold an additional 1,700 shares of common stock at a weighted average price of $13.99 per share.
- These sales were conducted in multiple transactions within a price range of $13.99 to $14.00.
- After the second transaction, Mr. Szot's direct beneficial ownership decreased to 17,133 shares of common stock.
- Both sales were executed in accordance with a pre-arranged Rule 10b5-1 trading arrangement.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it reports insider selling, the use of a Rule 10b5-1 plan mitigates concerns about opportunistic timing, indicating a pre-scheduled transaction rather than a reaction to new information.
Positives
- The transactions were conducted under a Rule 10b5-1 trading arrangement, indicating the sales were pre-scheduled and not based on immediate, non-public information.
Negatives
- Insider selling, even under a 10b5-1 plan, reduces the direct equity stake of a key executive in the company.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in the CFO's direct equity stake, which is primarily informational for existing and potential investors.
Key Dates
| Date | Description |
|---|---|
| 09/29/2025 | Transaction date for the sale of 100 shares of common stock by Matthew K. Szot. |
| 10/01/2025 | Transaction date for the sale of 1,700 shares of common stock by Matthew K. Szot. |
| 10/01/2025 | Date the Form 4 filing was signed by Matthew K. Szot. |
Keywords
Cadrenal Therapeutics, CVKD, Matthew K. Szot, Chief Financial Officer, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.